Hematology

“Rapid removal of antibodies is crucial in patients at high risk of organ dysfunction due to high antibody titers and severe symptoms associated with immunological disorders”.

Haematology

Hemophilias are inherited bleeding disorders caused by deficiencies in coagulation factors VIII or IX. The extent of the factor deficiency determines the likelihood and severity of bleeding. Following trauma, bleeding typically occurs in deep tissues or joints within a few hours. Diagnosis is confirmed through specific factor assays. In some cases, inhibitors of factor VIII are pathological antibodies that circulate and specifically neutralize the pro-coagulant activity of factor VIII. Factor VIII inhibitors therefore develop not only in patients with hemophilia A but also in non-hemophilic patients with autoimmune disorders (autoantibodies).

Treatment involves replacement of the deficient factor if acute bleeding is suspected. Alternatively, in cases where antibodies inhibit factor VIII activity, plasma exchange sessions are performed to rapidly and effectively remove the involved antibodies.

Molecules to remove: Specific autoantibodies/factor VIII inhibitors
Recommended Therapies: Plasma Exchange (PEX), Double filtration plasmapheresis (DFPP), Cascade Filtration

Macroglobulinemia is a rare neoplasm of the B-cell line, characterized by overproduction of IgM type M proteins, the cause of which is unknown. The main symptoms are related to a hyperviscosity syndrome: fatigue, weakness, skin deposits, bleeding from the skin and mucous membranes, visual disturbances, headache, symptoms of peripheral neuropathy, and other variable neurological manifestations.

Treatment includes sessions of plasma exchange, aimed at removing IgM and factors triggering hyperviscosity from the circulation, along with systemic therapy using alkylating agents, corticosteroids, nucleoside analogs, or monoclonal antibodies.

Molecules to remove: IgM Macroglobulins
Recommended Therapies: Plasma Exchange (PEX), Double filtration plasmapheresis (DFPP), Cascade Filtration

The presence of PP1Pk antibodies is considered one of the main causes of repeated spontaneous abortions in the early stages of gestation. PP1Pk antibodies circulate in the maternal blood and can negatively affect the fetus, causing irreversible issues. One of the possible therapeutic solutions for this pathological condition is plasma exchange. Administered throughout the gestational period until the birth of the baby, its goal is to remove this type of antibodies from the circulation.

Molecules to remove: PP1Pk antibodies
Recommended Therapies: Plasma Exchange (PEX), Double filtration plasmapheresis (DFPP), Cascade Filtration

Go to Plasmapher/Apherlungs system